Quantitative imaging biomarkers (QIB) are physical measurands assessed with clinical imaging techniques. They allow for more robust longitudinal assessments due to higher confidence in bias and precision, increased harmonization of image acquisition, and improved powering of endpoints. Validated QIBs can be acquired using standardized technical specifications, found in QIB Profiles.
MRI QIB Profiles
Magnetic Resonance Elastography of the Liver
November 2023
published by the MRE Biomarker Committee
Magnetic Resonance Diffusion-Weighted Imaging (DWI) of the Apparent Diffusion Coefficient (ADC)
December 2022
published by the DWI Biomarker Committee
CT QIB Profiles
Atherosclerosis Biomarkers by Computed Tomography Angiography (CTA)
June 2024
published by the CTA Biomarker Committee
Small Lung Nodule Volume Assessment and Monitoring in Low Dose CT Screening
June 2024
published by the SLN Biomarker Committee
CT Tumor Volume Change for Advanced Disease (CTV-AD)
July 2022
published by the VolCT Biomarker Committee
Nuclear/Molecular/PET QIB Profiles
QIBA Profile. FDG-PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy
June 2023
published by the FDG-PET Biomarker Committee
18F-labeled PET tracers targeting Amyloid as an Imaging Biomarker
June 2022
published by the PET Amyloid Biomarker Committee
Ultrasound QIB Profiles
Ultrasound Measurement of Shear Wave Speed for Estimation of Liver Fibrosis
January 2024
published by the Ultrasound SWS Biomarker Committee
SWS Checklists Appendix E
December 2023
published by the Ultrasound SWS Biomarker Committee
